• O-propargyl-puromycin (OPP): Protein Synthesis Detection in

  2026-07-31

  O-propargyl-puromycin (OPP) transforms protein synthesis measurement in living cells, providing unmatched specificity and workflow flexibility for immunology and proteomics research. This article details experimental setups, advanced applications, and troubleshooting, with practical guidance grounded in recent mechanistic studies of antibody-producing B cells.

• Nirmatrelvir (PF-07321332): Structural Insights and New Fron

  2026-07-30

  Explore the molecular basis and translational significance of Nirmatrelvir (PF-07321332) as a SARS-CoV-2 3CL protease inhibitor. This in-depth analysis reveals how structural understanding shapes novel antiviral therapeutics research and illuminates key experimental considerations.

• Sulfo-NHS-Biotin: Elevating Cell Surface Protein Labeling

  2026-07-30

  Sulfo-NHS-Biotin empowers selective, high-fidelity cell surface protein labeling with unmatched aqueous compatibility, as proven in advanced single-cell functional assays. This article breaks down applied workflows, troubleshooting strategies, and protocol optimizations to maximize reproducibility, drawing on both reference and peer-reviewed studies.

• Podophyllotoxin as a Precision Tool for Autophagy and Cell C

  2026-07-29

  Explore how Podophyllotoxin, a potent antineoplastic agent, serves as a precision instrument for dissecting autophagy and cell cycle arrest in cancer models. This article uniquely bridges mechanistic depth and translational assay strategy, offering new insight into optimizing research beyond established protocols.

• Tobramycin: Aminoglycoside Antibiotic Benchmarks & Applicati

  2026-07-29

  Tobramycin is a high-purity aminoglycoside antibiotic that inhibits bacterial protein synthesis and is essential for Gram-negative resistance research. Its spectrum, mechanistic benchmarks, and practical limitations are defined by rigorous in vitro evidence, making it a critical standard for microbiology workflows.

• Tomivosertib: Precision MNK1 Inhibitor Workflows in AML Rese

  2026-07-28

  Tomivosertib stands out as a highly selective MNK1 inhibitor, enabling researchers to dissect the MNK-eIF4E signaling pathway with exceptional specificity. Its robust inhibition of eIF4E phosphorylation supports advanced workflows in acute myeloid leukemia, neuronal, and metabolic models, with evidence-based protocol optimizations drawing from the latest translational studies.

• Mitochondrial Defects Drive AML Sensitivity to Mitocans

  2026-07-28

  The reference study systematically uncovers why acute myeloid leukemia (AML) cells are more sensitive to mitochondria-targeted anticancer agents than other tumor types. By linking unique mitochondrial metabolic defects in AML to heightened mitocan response, this work highlights mitochondrial function as a selective vulnerability in leukemia and guides future combinatorial therapy design.

• Temafloxacin: Fluoroquinolone Antibacterial Agent for Resear

  2026-07-27

  Temafloxacin empowers infection researchers with robust, reproducible workflows for both extracellular and intracellular pathogens. Explore detailed protocol parameters, advanced applications, and troubleshooting strategies that maximize the value of this fluoroquinolone broad-spectrum antibacterial agent.

• Elobixibat Hydrate: Transforming Bile Acid Transport in GI a

  2026-07-27

  This thought-leadership article examines the mechanistic depth, translational promise, and strategic future of Elobixibat hydrate as a selective ileal bile acid transporter inhibitor. Integrating clinical validation, competitive perspectives, and emerging research workflows, it provides translational investigators with a roadmap for leveraging Elobixibat hydrate in chronic idiopathic constipation, bowel preparation, and metabolic dysfunction studies. With a critical eye on maturity, limitations, and outlook, this piece establishes new scientific territory beyond standard product summaries.

• IDH2 Regulates TNBC Proliferation via Ferroptosis Suppressio

  2026-07-26

  This study demonstrates that isocitrate dehydrogenase 2 (IDH2) is highly expressed in triple-negative breast cancer (TNBC) and acts as a critical negative regulator of ferroptosis, thereby promoting tumor cell proliferation. Integrating multi-level validation, the research provides mechanistic insight into the metabolic vulnerabilities of TNBC and highlights ferroptosis as a promising therapeutic target.

• Ziprasidone Augmentation in Anxious Depression: Efficacy Ins

  2026-07-25

  This article discusses the nuanced findings from a randomized controlled trial that evaluated ziprasidone augmentation in patients with major depressive disorder, with a focus on those presenting with anxious depression. The study provides important evidence regarding the differential impact of ziprasidone HCl on anxiety and depressive symptoms, informing future directions for both clinical and translational research.

• GLP-1 (9-36) Amide: Unraveling Receptor Antagonism in Metabo

  2026-07-24

  Explore the advanced role of GLP-1 (9-36) amide as a glucagon-like peptide-1 receptor antagonist in metabolic regulation studies. This in-depth article provides scientific insights and experimental guidance beyond current resources.

• L-NAME Hydrochloride: Illuminating NO Pathways in Renal & Va

  2026-07-24

  Explore how L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) shapes mechanistic insight into nitric oxide signaling, apoptosis, and inflammation in renal and vascular models. This article uniquely bridges protocol guidance with translational findings from recent FXR-KLF11 pathway research.

• Concanamycin A: V-type H+-ATPase Inhibitor in Cancer Researc

  2026-07-23

  Concanamycin A stands out as a gold-standard V-type H+-ATPase inhibitor, enabling precise interrogation of endosomal acidification and apoptosis in cancer biology. This article details practical protocols, advanced use-cases, and troubleshooting strategies to maximize experimental reliability with APExBIO’s Concanamycin A.

• Angiotensin II in Vascular Remodeling: Protocols & Innovatio

  2026-07-23

  Angiotensin II, the endogenous octapeptide Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, is indispensable for modeling hypertension and vascular injury in both cell and animal systems. This article delivers advanced, evidence-backed workflows, protocol refinements, and troubleshooting strategies for maximizing reproducibility and insight in cardiovascular and renal research using APExBIO’s Angiotensin II.

444 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page